Heterochromatin underpins gene repression, genome integrity, and chromosome segregation. In the fission yeast *Schizosaccharomyces pombe*, conserved protein complexes effect heterochromatin formation via RNA interference-mediated recruitment of a histone H3 lysine 9 methyltransferase to cognate chromatin regions. To identify small molecules that inhibit heterochromatin formation, we performed an *in vivo* screen for loss of silencing of a dominant selectable *kanMX* reporter gene embedded within fission yeast centromeric heterochromatin. Two structurally unrelated compounds, HMS-I1 and HMS-I2, alleviated *kanMX* silencing and decreased repressive H3K9 methylation levels at the transgene. The decrease in methylation caused by HMS-I1 and HMS-I2 was observed at all loci regulated by histone methylation, including centromeric repeats, telomeric regions, and the mating-type locus, consistent with inhibition of the histone deacetylases (HDACs) Clr3 and/or Sir2. Chemical-genetic epistasis and expression profiles revealed that both compounds affect the activity of the Clr3-containing Snf2/HDAC repressor complex (SHREC). *In vitro* HDAC assays revealed that HMS-I1 and HMS-I2 inhibit Clr3 HDAC activity. HMS-I1 also alleviated transgene reporter silencing by heterochromatin in *Arabidopsis* and a mouse cell line, suggesting a conserved mechanism of action. HMS-I1 and HMS-I2 bear no resemblance to known inhibitors of chromatin-based activities and thus represent novel chemical probes for heterochromatin formation and function.
tional silencing (15, 16). SHREC consists of the HDAC Clr3, the SNF2-related chromatin remodeling factor Mti1, and two nonenzymatic components, Clr1 and Clr2 (15). The HDACs Clr6 and Sir2 also facilitate removal of histone acetylation to maintain heterochromatin integrity (17–19). SHREC resembles the vertebrate Mi-2/ NuRD silencing complex, which contains HDAC1/2 and SNF2 ATPase Mi-2, among other proteins (20), although it remains unclear whether RNAi directly modulates chromatin modification in mammals (1). Related protein complexes are known to couple RNAi to DNA methylation, H3K9 methylation, and gene silencing in plants (21, 22). In Arabidopsis, RNAi also contributes to heterochromatin integrity by directing de novo DNA methylation to homologous sequences (23, 24), where it recruits Suv39 methyltransferase related proteins (25).

RNAi and heterochromatin components are not essential for viability of fission yeast. This has facilitated mechanistic dissection of the process initially through genetic screens and subsequently via mass spectrometric analysis of purified protein complexes (10, 15, 26–29). Deletion of individual RNAi or heterochromatin components disrupts silencing of reporter genes inserted within heterochromatin (10, 15, 28, 30). Small-molecule inhibitors provide an alternative means for probing biological pathways. In contrast to mutations, inhibitor effects are usually reversible and thereby enable precise determination of functional dependencies in complex pathways (31–33). For example, in vivo screens based on telomere position effect in budding yeast have previously allowed the identification of sirtinol (10, 26–29). Deletion of individual RNAi or heterochromatin components disrupts silencing of reporter genes inserted within heterochromatin (10, 15, 28, 30). Small-molecule inhibitors provide an alternative means for probing biological pathways. In contrast to mutations, inhibitor effects are usually reversible and thereby enable precise determination of functional dependencies in complex pathways (31–33). For example, in vivo screens based on telomere position effect in budding yeast have previously allowed the identification of sirtinol (10, 26–29).

Compounds That Disrupt Heterochromatin Integrity

### MATERIALS AND METHODS

**Fission yeast growth and chemical screens.** Haploid Schizosaccharomyces pombe cells were grown in YES (yeast extract with supplements) medium at 32°C and assessed in log phase for all experiments. Cells and compounds were dispensed in 96-well microplates using a Biomek FX liquid handling robot (Beckman Coulter) and plates were read (optical density at 595 nm [OD595]) every 15 min for 48 to 72 h at 32°C with continuous shaking in a Sunrise plate reader (Tecan). Growth curves generated for each compound were analyzed using in-house R scripts and the grofit R package to extract parameters for doubling time, lag time and saturation time. Table 1 contains a list of the strains used in the present study.

**Characterization of chemical compounds.** 1H and 13C NMR, recorded at 400 and 100 MHz, respectively, were performed on a Varian 400-ORMR spectrometer. Assignments of 1H and 13C NMR signals were carried out by correlation spectroscopy (COSY) and Heteronuclear Single Quantum Coherence (HSQC) experiments. Mass spectral data (MS) and high-resolution mass spectrometry (HRMS) data were recorded on Agilent 6120 Quadrupole LC/MS and Agilent LC/MSD TOF (model 61969A) systems, respectively.

Yeast growth was scored on YES plates containing compounds at concentrations ranging from 2 to 200 μg/mL. Positive growth was recorded if colony size was greater than that of the negative control for each genotype. Strains were scored in triplicate from three separate experiments. Each experiment was performed in duplicate, and at least 100 colonies were scored per replicate. Results were confirmed by growth on YES plates with the indicated compounds at 100 μg/mL.

**Table 1** Fission yeast strains used in this study

<table>
<thead>
<tr>
<th>Strain</th>
<th>Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1056</td>
<td>mat1::ura4 ade6-210 leu1-32 ura4-177</td>
</tr>
<tr>
<td>9962</td>
<td>h·Δclr3::kanMX ade6-210 ura4-D18 leu1-32</td>
</tr>
<tr>
<td>8878</td>
<td>h·Δclr3::kanMX ade6-210 leu1-32 arg3-D4 his3-D ura4-D18</td>
</tr>
<tr>
<td>9299</td>
<td>b90 mat::ura4-1 ura4-DS/E drl1-D::NAT</td>
</tr>
<tr>
<td>9351</td>
<td>h·Δclr3::kanMX his3D arg3-D4 leu1-32 ade6-210 ura4-D18</td>
</tr>
<tr>
<td>17425</td>
<td>h·Δclr1::KanMX orf18(phen) ade6-210 leu1-32 ura4-D18</td>
</tr>
<tr>
<td>17668</td>
<td>h·Δclr1::KanMX sir2::NatMX ade6-210 leu1-32 ura4-D18</td>
</tr>
<tr>
<td>17860</td>
<td>h·Δclr1::KanMX sir2::NatMX ade6-210 leu1-32 ura4-D18 his3-D1</td>
</tr>
<tr>
<td>18161</td>
<td>h·Δclr3::KanMX sir2::NatMX ade6-704-HygMX6 leu1-32 ura4-D18</td>
</tr>
<tr>
<td>19650</td>
<td>Mat1-Montol leu1-32 ade6-210 his2 ura4-D5/SU clr1-3×FLAG-KanMX orf1R(SphI)::ura4-1</td>
</tr>
<tr>
<td>20079</td>
<td>h·Δade6-210 leu1-32 ura4-D18 imr1R (dg-glu) NcoI::KanMX orf11</td>
</tr>
<tr>
<td>20080</td>
<td>h·Δade6-210 leu1-32 ura4-D18 imr1R (dg-glu) NcoI::KanMX orf1II</td>
</tr>
<tr>
<td>20303</td>
<td>h·Δhis2 ura4-D18 ade6-216 ura4-D18 his2-366 leu1-32</td>
</tr>
<tr>
<td>20304</td>
<td>h·Δade6-210 leu1-32 ura4-D18 leu1-32</td>
</tr>
<tr>
<td>20305</td>
<td>h·Δmit1::KanMX ade6-210 ura4-D18 leu1-32</td>
</tr>
<tr>
<td>20306</td>
<td>h·Δmit1::KanMX ade6-210 ura4-D18/SU leu1-32</td>
</tr>
<tr>
<td>SPT429</td>
<td>Mat1-Montol leu1-32 ade6-210 his2 ura4-D5/SU mit1-13×myc-KanMX orf1R(SphI)::ura4-1</td>
</tr>
</tbody>
</table>

The data obtained for compound 2-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-6-methylimidazo[1,2-a]pyridine (HMS-11) were as follows: (i) 1H NMR (400 MHz, CDCl3): 6 (ppm) 7.87 (7H, 1H, MeCCCHN), 7.66 (6H, 1H, NCCCH), 7.50 (d, J = 9.00 Hz, 1H, NCCCH), 7.41 to 7.47 (m, 2H, O-CHCC), 6.99 (dd, J = 1.17, 9.39 Hz, 1H, MeCCCH), 6.92 (d, J = 7.83 Hz, 1H, p-OCCH), 4.30 (s, 4H, OCH2), 2.31 (s, 3H, CH3); (ii) 13C NMR (100 MHz, CDCl3); 6 (ppm) 145.4, 144.8, 143.9, 143.6, 127.8, 127.7, 127.4, 122.0, 119.4, 117.6, 116.8, 115.0, 107.3, 64.6, 64.5, 18.2; (iii) 13C NMR (100 MHz, CDCl3, CH3C(O)CH2) from HSQC; 6 (ppm) 127.7 (MeCCCH), 123.4 (MeCCCH), 119.4 (p-OCCH), 117.7 (p-OCCH), 116.8 (NCCCH), 115.1 (m-OCCH), 107.3 (NCCCH), 64.5 (OCH2), 18.2 (CH2); (iv) HRMS (ESI-TOF) m/z: [M + H]+ calculated for C14H13N2O2 267.1128; found 267.1137.

The data obtained for compound N-(benzo[b]thiophen-2-yl)-4-(2-chloro-6-fluorobenzyl)piperazine-1-carboxamide (HMS-12) were as follows: (i) 1H NMR (400 MHz, CDCl3); 6 (ppm) 7.72 (dd, J = 7.92 Hz, 1H), 7.55 (d, J = 7.63 Hz, 1H), 7.13 to 7.32 (m, 4H), 6.96 to 7.06 (m, 2H, ArCH2NH), 6.73 (s, 1H), 3.76 (d, J = 2.35 Hz, 2H, CH Ar), 3.45 to 3.59 (m, 4H, CH2NCC); 2.59 to 2.66 (m, 4H, CH2NCC); (ii) 13C NMR (100 MHz, CDCl3, 2H, C(1,2) or 2H, C(3,4) from HSQC); 6 (ppm) 129.4 (CH), 125.6 (CH), 124.3 (CH), 122.4 (CH), 121.8 (CH), 121.5 (CH), 114.0 (CH), 105.2 (CH), 52.3 (CH Ar), 32.9 (CH NCC), 44.2 (CH NCC); (iii) LC-MS (APCI) m/z: [M + H]+ calculated for C20H17CIFN6O4S 401.2404; found 401.4.
TABLE 2 Primers or probes used in this study

<table>
<thead>
<tr>
<th>Primer or probe</th>
<th>Sequence (5’–3’)</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>qPCR primers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>act1</td>
<td>CCAAAATCAACCGTGAGGATG</td>
<td></td>
<td>CGGAGTCTCAGAGCGTACCCAGT</td>
</tr>
<tr>
<td>kanMX</td>
<td>GCCGTGTGGAACAGTCG</td>
<td></td>
<td>TCCGACTCAGACCAATCTC</td>
</tr>
<tr>
<td>cen(dg)</td>
<td>AATTGTGTTGTGGTTGTTAAC</td>
<td></td>
<td>GGCTTACGTTTTCATTTCAG</td>
</tr>
<tr>
<td>mat</td>
<td>GTCCGAGCAATCACTTTGG</td>
<td></td>
<td>GGTGTCATAGGAATATATTCAG</td>
</tr>
<tr>
<td>thl</td>
<td>GGATAAAGCATACTTTGTTAG</td>
<td></td>
<td>GTATGGTGACGTCTTTGGAG</td>
</tr>
<tr>
<td>Pc</td>
<td>CAGGTCTGTCAGGCAATATG</td>
<td></td>
<td>GCTATGGTACGAAAGGAG</td>
</tr>
<tr>
<td>Pi</td>
<td>CACTAACCCACCTTTGTAGC</td>
<td></td>
<td>GGCTGACAGTGGTAAGATTT</td>
</tr>
<tr>
<td>Mc</td>
<td>CCGTGTGTTGGGAAATTCTCTG</td>
<td></td>
<td>AAAAGATTTGGGGGTCTGGG</td>
</tr>
<tr>
<td>eGFP</td>
<td>AGGCTATGGTCAGGAGAGA</td>
<td></td>
<td>ATTACCGAGGTGGAATAG</td>
</tr>
<tr>
<td>amylase</td>
<td>TTTCGTGCGTTTCTCCTATT</td>
<td></td>
<td>CGAAGGCTGAGGAAATAG</td>
</tr>
<tr>
<td>GAPDH</td>
<td>ACCCAGAGAGCTGGTGGAGG</td>
<td></td>
<td>CATCTGCTGGGGAGG</td>
</tr>
<tr>
<td>HDAC6</td>
<td>TAAGGAAATGACCAACAGGA</td>
<td></td>
<td>CTGAGACAGCAGACCTT</td>
</tr>
<tr>
<td>HDAC10</td>
<td>TGGATGGCTCATCCAGAAGA</td>
<td></td>
<td>TCTATACGCCATCCATC</td>
</tr>
<tr>
<td>Northern probes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IK8</td>
<td>ATTCCTTCTTGGACACCTTCCTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IK9</td>
<td>TTGTATGGCCATGTTCCATCCCTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IK10</td>
<td>GGGAGTACATCATTTCTCTGATA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>snR58</td>
<td>GATGAAATCCAGAAGTCTC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ChiP. Chromatin immunoprecipitation (ChiP) analysis was performed as previously described (47). Briefly, cells were grown at 32°C to log phase and fixed in 1% formaldehyde for 15 min at room temperature. Cells were lysed with a bead beater (Biospec Products) and sonicated using a BioRuptor sonicating water bath (Diagenode) for 15 min (30-s duty cycle). For immunoprecipitations, H3K9me2 (m5.1.1 [48]), H3K9ac (Active Motif, catalog no. 39137), H3K14ac (Millipore, catalog no. 07-353), Flag M2 (Sigma, catalog no. F1804), and c-Myc (Santa Cruz, catalog no. 9B11) antibodies were incubated overnight with the lysate. After bead washes, samples were treated with Chelex resin, followed by incubation with proteinase K. Samples were diluted and used in quantitative PCRs (qPCRs).

RNA analyses. Reverse transcription-PCR (RT-PCR) of centromeric outer repeat transcripts and Northern analysis of centromeric siRNAs were performed as previously described (47, 49, 50).

qPCRs. ChiP and RT-PCR samples were quantified by qPCRs carried out with SYBR green on a LightCycler 480 instrument (Roche). The data were analyzed using Light Cycler 480 software 1.5 (Roche). For ChiP, enrichment was calculated as the ratio of target sequence to control sequence (act1) in the immunoprecipitated sample over input lysate. For RT-PCR, quantification was relative to untreated dimethyl sulfoxide (DMSO) control using act1/GAPDH as a negative region. Histograms represent mean and standard deviation for three biological replicates. Statistical significance was assessed by using the Student t test comparing compound-treated strains with untreated strains of the same genotype or mutant strains with the wild-type strain. Table 2 lists the primers used in the present study.

Microarray analysis of gene expression. Total RNA was extracted from S. pombe cells using the hot phenol method (51). RNA was purified with an RNAsafe mini-kit (Qiagen) and tested for integrity on a 2200 TapeStation (Agilent). 150 nanograms of RNA was used for labeling and array hybridization using GeneChip S. pombe tiling 1.0FR microarrays according to the GeneChip Whole Target labeling and hybridization protocol (Affymetrix). The data were normalized with quantile normalization plus scaling using Tiling Analysis Software (TAS) 1.1 and imported into the Podbat browser program (52). Podbat was used to produce upregulated gene lists for the different treatments using settings for various fold changes and a P value of <0.05. GeneSpring GX software (Agilent Technologies) was used to compare the gene lists obtained for compound treatments with the gene lists for various S. pombe mutants present in an in-house database in the Ekwall laboratory. Cutoffs of 1.28 and 1.5 were used for the HMS-1 and HMS-2 treatments, respectively, to recover a comparable number of genes for both treatments. Biological duplicates were prepared and analyzed for each condition.

Plant growth and histochemistry. The transgenic Arabidopsis thaliana L5 line has been described elsewhere (53). Seeds were surface sterilized and sown on MS agar plates with 15 g/liter sucrose. Plates were cold treated for 2 days at 4°C. Seedlings were grown at 20°C under fluorescent white light (fluence rate of 40 to 60 μmol m−2 s−1) with a 16-h light/8-h dark photoperiod. At 12 days postgermination, seedlings were transferred to liquid MS in a 40-ml flask and, after 24 h, 10 μM HMS-11, 10 μM HMS-12, or DMSO was added. Compound treatment was repeated 3 days later, and samples were collected 2 days later. β-Glucuronidase (GUS) staining was performed as previously described (54) with minor modifications. Plant tissues were immersed in histochemical GUS staining buffer (100 mM NaPO4, 0.5 mM KFe(CN)6, 0.5 mM K4Fe(CN)6, 20% cations). Plant growth and histochemistry. Murine erythroleukemia (MEL) suspension cells were grown in Dulbecco modified Eagle medium (Gibco) with fetal bovine serum and penicillin-streptomycin at 37°C in the presence of each compound or DMSO solvent control. fluorescence-activated cell sorting (FACS) analysis of enhanced green fluorescent protein (eGFP) expression was performed with a Becton Dickinson FACS analyzer. For ChiP analysis, MEL cells were grown for 3 days in the presence of compounds and then fixed with 1% formaldehyde for 5 min at room temperature. Immunoprecipitated DNA was obtained with antibodies to H3K9me2 (Uranoo; Kimura 007) and H3K9me3 (Abcam; Kimura 008). Quantitation of ChiP was performed by qPCR as described above.

Recombinant CrI3 protein production. Using the MultiBac system (55), CrI3 was expressed in Sf9 insect cells as an N-terminal fusion of the codon optimized sequence to a multifunctional tag composed of OneStep-Sumostar (OSS) (36), T7 tag, and a TEV site. The OSS-CrI3 protein was purified on a StreptTrap column (GE Healthcare), cleaved from the tag using tobacco etch virus (TEV) protease, and purified to homogeneity by gel filtration on Superdex 200 (GE Healthcare) in 10
mM HEPES (pH 7.6), 200 mM KCl, 1 mM dithiothreitol, and 50 mM magnesium acetate.

In vitro HDAC assays. Clr3 assays were performed with an HDAC fluorometric assay kit from BioVision (K330-100) according to the manufacturer’s instructions. Recombinant human HDAC assays were performed by Reaction Biology (Malvern, PA). Compounds and purified recombinant HDACs were preincubated 20 min in assay buffer (50 mM Tris-HCl [pH 8.0], 137 mM NaCl, 2.7 mM KCl, and 1 mM MgCl₂, 1 mg/ml bovine serum albumin, 1% DMSO), before the addition of 50 μM fluorogenic substrate [Arg-His-Lys-Lys(Ac)-AMC]. Reaction mixtures were incubated for 2 h at 30°C. The deacetylated substrate was then cleaved by trypsin, which released the fluorescent 7-amino-4-methylcoumarin. Fluorescent signals were read with an EnVision multilabel plate reader (Perkin-Elmer).

siRNA knockdown of HDAC6 and HDAC10 in MEL cells. Cells were transfected with sense and antisense small interfering RNA (siRNA) at a final concentration of 100 nM (HDAC6 sense, GGAGGAAGAUGAAGUGGAAuu; HDAC10 sense, GGACAAGCCUCCAGCAAAAuu) with DharmaFECT2 reagent. Cells were collected 48 h after transfection. Scrambled siRNAs were included as controls. Statistical significance was assessed by using the Student t test comparing HDAC6/10 siRNA with scrambled siRNA treatments.

GEO accession number. All microarray data are available under GEO accession number GSE57207.

RESULTS
Small-molecule inhibitors of fission yeast centromeric heterochromatin integrity. To screen for inhibitors of fission yeast het-
erochromatin integrity, we constructed a reporter strain harbor-
ing a dominant selectable kanamycin (*kanMX*) reporter gene
within the heterochromatin of centromere 1 (*cen1*). The
*kanMX* gene was inserted in the innermost repeats (*imr*) on the right side
of *cen1* [NcoI]: *kanMX*, abbreviated as *cen1-kanMX* (Fig. 1A). Expression of
*kanMX* normally confers resistance to G418, but because in
*cen1-kanMX* cells the reporter gene is si-
lenced by surrounding heterochromatin, these otherwise wild-
type cells exhibit sensitivity and grow poorly on plates containing
G418. Disruption of heterochromatin by deletion of the gene en-
coding Clr4 methyltransferase (*clr4*/*H9004*) allowed expression of
*cen1-kanMX* and resistance to G418 and thus increased growth on
G418 medium (Fig. 1B). Microwell-based liquid culture growth
assays, performed with or without G418 on *cen1-kanMX* cells,
enabled the reproducible detection of G418 resistance in
*clr4/*H9004* cells compared to wild-type (*wt*) cells by continual monitoring of
optical density. Addition of the known Sirtuin HDAC inhibitor
nicotinamide also resulted in increased growth of wild-type cells
in the presence of G418 (Fig. 1C). This validated
*cen1-kanMX* reporter strain was subsequently used to screen 1,570 compounds
that had been previously selected for chemical diversity andbio-
activity (57). Two compounds, 2-(2,3-dihydro-1,4-benzo[
**b**][1,4]dioxin-6-yl)-6-methylimidazo[1,2-**a**]pyridine
and N-(1-benzo-[**b**](hiphen-2-yl)-4-(2-chloro-6-fluorobenzyl)piperazine-1-car-
boxamide, here referred to as HMS-I1 and HMS-I2, respectively
(heterochromatin-mediated silencing inhibitors 1 and 2), were
identified as reproducible hits that increased the resistance of
wild-type *cen1-kanMX* cells to G418 to a similar extent as nicoti-
namide (Fig. 1C and D).

To our knowledge, biological activity for HMS-I1 and HMS-I2
has not been reported previously. Although HMS-I1 and HMS-I2
could conceivably fit into a common pharmacophore model, their
structural disparities precluded straightforward conclusions. For
instance, the imidazopyridine and piperazine carboxamide cores
of HMS-I1 and HMS-I2, respectively, feature different numbers
and placement of hydrogen bond donors/acceptors, while their
lipophilic flanking groups differ in size and shape. HMS-I1 and
HMS-I2 lack compelling structural similarities to well-established
inhibitors of chromatin-modifying enzymes such as HDAC inhib-
itors (58, 59). We note that HMS-I1 and HMS-I2 do not contain
canonical zinc chelating moieties possessed by type I and II HDAC
inhibitors: HMS-I1 cannot form a chelate due to a lack of heteroa-
toms disposed in a 1,4 relationship and the conceivable chelation
modes for HMS-I2 are electronically and sterically suboptimal.

A hallmark of centromeric heterochromatin is the presence of
methylated histone H3K9 (*H3K9me*) chromatin over the centro-
meric repeats and inserted marker genes. Disruption of centro-
meric heterochromatin results in reduced levels of H3K9me and
loss of silencing of inserted marker genes (28, 47, 60). Quantitative
ChIP (qChIP) analyses on cells grown under G418 selection re-
vealed that HMS-I1 and HMS-I2 caused substantial loss of
*cen* (*dg*) relative to *act1* transcript levels and normalized to relative levels in wild-type cells. Error bars indicate standard deviations from two biological replicates. *, *P* < 0.05; **, *P* < 0.01; ***, *P* < 0.0001. HMS-I1 and HMS-I2 were used at a concentration of 5 μM in panels A to D. The media contained 10 μg/ml G418 in panels A, C, and D.
elements (Fig. 1E). Importantly, the qChIP assay monitored H3K9me2 associated with the 18 copies of otr/dg centromere repeats distributed over the three centromeres. HMS-I1 and HMS-I2 thus altered the status of H3K9 methylation across all three centromeres, demonstrating that the compounds affect heterochromatin throughout the nucleus and not just at the selected cen1-kanMX locus. Neither compound induced a complete loss of H3K9me2, as observed in cells lacking Clr4 H3K9 methyltransferase (clr4/H9004) (Fig. 1E). Growth of cen1-kanMX cells in the presence of HMS-I1 or HMS-I2, but in the absence of G418 selection, had less dramatic effects since the H3K9me2 levels were lower on kanMX but not on the native outer repeat sequences (data not shown and see Fig. 3).

Histone hypoacetylation is also a hallmark of heterochromatin, and an increase in histone lysine acetylation is expected to accompany the loss of centromeric marker gene silencing. Consistently, we observed an increase in H3K9 and H3K14 acetylation on cen1-kanMX in cells treated with HMS-I1 and HMS-I2 grown in the presence of G418 (Fig. 1F). We conclude that HMS-I1 and HMS-I2 increase the G418 resistance of cen1-kanMX cells by general disruption of centromeric heterochromatin and concomitant elevated expression of the embedded kanMX resistance gene.

HMS-I1 and HMS-I2 inhibit events downstream of RNAi in chromatin modification and heterochromatin formation. RNAi is required for both the establishment and the maintenance of centromeric heterochromatin in fission yeast (61–63). In contrast, following RNAi-triggered establishment of heterochromatin domains over the mat2-mat3 region of the mating-type locus or adjacent to telomeres, RNAi is not continuously required to maintain heterochromatin since alternative pathways propagate heterochromatin at these locations (64–67). ChIP analyses showed that, as expected, H3K9me2 was lost at mat2-mat3 and telomeres in cells that lacked Clr4 H3K9 methyltransferase, or the HDACs Clr3 and Sir2, but was retained in cells that lack RNAi due to deletion of Dcr1. H3K9me2 levels were also consistently reduced at both mating-type and subtelomeric regions when cen1-kanMX cells were incubated with HMS-I1 or HMS-I2 and selected for G418 resistance (Fig. 2A and data not shown).

FIG 3 Clr3 is a putative target of HMS-I1 and HMS-I2. qChIP analysis of H3K9me2 levels associated with centromeric repeats [cen1(dg)], relative to act1+ Cells were grown in the presence of 5 μM HMS-I1 or HMS-I2 and without G418 selection. Error bars indicate standard deviations for three biological replicates. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.

FIG 4 HMS-I1 and HMS-I2 mimic the effect of SHREC mutations on gene expression. (A) Overlap between gene sets upregulated in cells grown in the presence of HMS-I1 and HMS-I2. (B) Expression profiles of cells grown in the presence of HMS-I1 or HMS-I2 compared to the indicated SHREC mutants. The P value (hypergeometric probabilities) of the overlap between gene lists is indicated in cases where a statistical significance was observed. Genes upregulated in cells that lack RNAi (ago1/H9004 and dcr1/H9004) or the Sir2 HDAC (sir2/H9004) were also compared but showed no significant overlap with those upregulated by HMS-I1 and HMS-I2 treatment. *, data from Hansen et al. (69); **, data from Wiren et al. (18); ***, data from the present study (see Data set S1 in the supplemental material). Cells were grown in YES medium with 5 μM HMS-I1 or HMS-I2 and 10 μg/ml G418 in panels A and B. Comparisons in panels A and B are restricted to annotated genes present in the Ekwall laboratory in-house database.
Heterochromatin-mediated silencing at the mating-type locus ensures that the silent mating-type cassettes encoding plus (P) or minus (M) information (mat2-P and mat3-M) cannot be expressed. These cassettes must normally be recombined into the active mat1 expression site to escape the powerful repressive heterochromatin environment of the silent loci and allow expression. Mutations in CLRC (Clr4-Rik1-Cul4) complex and HDAC components are known to alleviate transcriptional silencing at the mat2-P and mat3-M loci (26). Strikingly, treatment of a sterile yeast strain lacking the mat1 expression site (i.e., a mat1Δ strain that lacks the kanMX reporter gene) with HMS-I1 and HMS-I2 resulted in the expression of Pc/Pi and Mc transcripts, respectively (Fig. 3). HMS-I1 and HMS-I2 exhibited strong chemical-genetic interactions with either Clr3- or Sir2-related functions. Epistasis analysis has shown that RNAi operates in a parallel pathway to the HDACs Clr3 and Sir2 to maintain heterochromatin integrity at centromeres (61, 62, 68). Cells devoid of an RNAi component such as Dcr1, or either the Clr3 or Sir2 HDACs, retain significant levels of H3K9me on centromeric repeats. However, the removal of both Dcr1 and Clr3 or Sir2 reduces H3K9me to much lower levels than that observed in dcr1Δ, clr3Δ or sir2Δ cells. These results demonstrate that HMS-I1 and HMS-I2 phenocopy the loss of Clr3 and Sir2 and suggest that both compounds might interfere with either Clr3- or Sir2-related functions.

The Clr3 HDAC is a putative target of HMS-I1 and HMS-I2. Epitasis analysis has shown that RNAi operates in a parallel pathway to the HDACs Clr3 and Sir2 to maintain heterochromatin integrity at centromeres (61, 62, 68). Cells devoid of an RNAi component such as Dcr1, or either the Clr3 or Sir2 HDACs, retain significant levels of H3K9me on centromeric repeats. However, the removal of both Dcr1 and Clr3 or Sir2 reduces H3K9me to much lower levels than that observed in dcr1Δ, clr3Δ or sir2Δ cells. These results demonstrate that HMS-I1 and HMS-I2 phenocopy the loss of Clr3 and Sir2 and suggest that both compounds might interfere with either Clr3- or Sir2-related functions.
HMS-I2 interfere with the function of either the HDAC Clr3 and/or associated proteins in the SHREC complex. HMS-I1 and HMS-I2 mimic the effect of SHREC mutations on gene expression. Previous genome-wide expression profiles showed that the Clr3 HDAC is required to repress expression of a broad cohort of genes (183 genes > 1.5-fold upregulated in clr3-735 [69]). Clr3 has been shown to associate with Clr1, Clr2, and Mit1 within the repressive SHREC complex, and all four components contribute to heterochromatin integrity (15). If HMS-I1 and HMS-I2 interfere with Clr3 or SHREC function as predicted, then each compound should cause induction of a gene set that overlaps with that upregulated in SHREC mutant cells. In cells grown in the presence of compounds and G418, HMS-I1 and HMS-I2 increased the expression of 37 and 200 genes by >1.5-fold, respectively. Significant overlap was evident between the sets of genes affected by HMS-I1 and HMS-I2: 36 of the 37 genes upregulated 1.5-fold by HMS-I1 were also upregulated 1.5-fold by HMS-I2 (P = 3.28 × 10^{-53}) and 131 of the 200 genes upregulated 1.28-fold by HMS-I1 were also upregulated 1.5-fold by HMS-I2 (P = 1.09 × 10^{-175}) (Fig. 4A; see Data set S1 in the supplemental material). Compared to expression profiles for clr1-5, clr2Δ, clr3-735, and mit1Δ strains (69) (see also Data set S1 in the supplemental material), we observed significant overlap between genes derepressed in the SHREC mutants and HMS-I1 or HMS-I2 treated cells (Fig. 4B). No significant overlap was detected when we compared genes upregulated by HMS-I1 or HMS-I2 with those increased in cells that lack RNAi components (ago1Δ and dcr1Δ; Fig. 4B). Previous analyses showed that Clr3 and Sir2 mediate the repression of an overlapping set of genes (18), which explains the few genes whose expression increases after exposure to HMS-I1 or HMS-I2 and that are also upregulated in sir2Δ cells (Fig. 4B). However, the overlap between genes upregulated by HMS-I1 and HMS-I2 and those upregulated in sir2Δ cells is not significant. Based on this analysis of global gene expression, we conclude that the SHREC complex is a likely target for the inhibitory activity of both HMS-I1 and HMS-I2.

HMS-I1 and HMS-I2 reduce in vitro Clr3 HDAC activity. The genetic analyses described above indicate that HMS-I1 and HMS-I2 impede the activity of the fission yeast SHREC complex, which contains the type II HDAC Clr3. We first assessed whether HMS-I1 and HMS-I2 acted by preventing the recruitment of SHREC components at heterochromatin. ChIP analyses showed that neither HMS-I1 nor HMS-I2 affected the recruitment of either the Clr3 HDAC or the Mit1 chromatin remodeling components of SHREC to mating-type or centromeric heterochromatin (Fig. 5A and B). To determine whether these compounds exert their effect on SHREC function through inhibition of Clr3 catalytic activity, we performed in vitro fluorescence-based HDAC assays. HMS-I1 and HMS-I2 reproducibly reduced the activity of Clr3 by 40 and 80%, respectively (Fig. 5C and D). Under these assay conditions, HMS-I2 inhibits Clr3 to a greater extent than HMS-I1, a finding consistent with the greater reduction in H3K9 methylation observed in HMS-I2-treated sir2Δ and dcr1Δ cells and the greater increase in gene expression caused by HMS-I2 (see Fig. 3 and 4). Collectively, these data suggest that HMS-I1 and HMS-I2 are inhibitors of Clr3 HDAC activity.

HMS-I1 and HMS-I2 disrupt transgene silencing in multicellular eukaryotes. To assess whether HMS-I1 and HMS-I2 might also disrupt heterochromatin integrity in multicellular eukaryotes, we tested for the effects on gene silencing in plants and mammalian cells. We first tested whether HMS-I1 and HMS-I2 could alleviate reporter gene silencing in the Arabidopsis thaliana L5 transgenic line, which contains a transcriptionally silenced GUS transgene (53). HMS-I1 caused an increase in the GUS reporter
expression in the root and leaf tissue, whereas HMS-I2 alleviated silencing in the leaf tissue only (Fig. 6). Transcriptional gene silencing mutants reactivate the expression of GUS, whereas RNAi mutants do not (70), indicating that, as in fission yeast, HMS-I1 and HMS-I2 mediate their effects in Arabidopsis independently of RNAi.

We next assessed the effect of the compounds on reporter gene silencing in MEL cells. A β-globin gene promoter-driven eGFP reporter is known to be silenced and coated in repressive H3K9 methylated chromatin at the RL5 locus in these MEL cells when vector backbone bacterial DNA is inserted upstream of the transgene (designated RL5/pYB) (Fig. 7A) (71). In addition, the inclusion of an array of human α-satellite repeats upstream of the reporter (designated RL5/pYB-αSat) (Fig. 7A) bolsters eGFP silencing and H3K9me levels across the transgene (71). We utilized both RL5/pYB and RL5/pYB-αSat MEL cell lines to determine whether HMS-I1 or HMS-I2 interfere with the integrity of heterochromatin at the reporter locus. FACS analysis of the RL5/pYB and RL5/pYB-αSat cell lines showed that eGFP expression increased over time with HMS-I1 but not with HMS-I2 (Fig. 7B). Thus, growth in the presence of HMS-I1 overcomes the strong silencing mediated by α-satellite repeats in MEL cells.

To determine whether HMS-I1 also alters H3K9 methylation levels associated with silent transgenes in multicellular eukaryotes, we performed ChIP analysis with the RL5/pYB-αSat cell line, for which the observed effect on silencing was the strongest. A substantial decrease in both H3K9me2 and H3K9me3 levels associated with the eGFP reporter occurred after 3 days of incubation with HMS-I1. Furthermore, a reduction in H3K9 methylation was also detected on the endogenous mouse amylase gene (Fig. 7C) that is normally repressed in MEL cells (72). Thus, HMS-I1 can disrupt heterochromatin associated with endogenous repressed genes, in addition to that formed by mammalian repetitive elements over the β-globin/eGFP reporter.

In S. pombe, our data suggested that the type II HDAC Clr3 is a target of HMS-I1. Although the identity of HMS-I1 target(s) in mammalian cells remains to be defined in vivo, an in vitro HDAC assay performed with a panel of human recombinant enzymes indicated that HMS-I1 reduced the activity of the type IIb HDACs, HDAC6 and HDAC10 (Fig. 8A). Consistent with inhibition of these HDACs, siRNA knockdown of either HDAC6 or HDAC10 expression resulted in increased β-globin–eGFP transcript levels in both RL5/pYB and RL5/pYB-αSat MEL cell lines compared to scrambled siRNA controls (Fig. 8B and C). Collectively, these results suggest that HMS-I1, and possibly also HMS-I2, derepress transcriptionally silent heterochromatin in evolutionarily distant species through inhibition of conserved HDACs.

**DISCUSSION**

Heterochromatin is tightly associated with transcriptional silencing in most eukaryotes and is particularly prevalent over repetitive elements, where it prevents inappropriate recombination events and genome rearrangements (3). The aberrant silencing of genes through unscheduled heterochromatin formation is known to contribute to several human diseases, including acute myeloid leukemia and Friedreich’s ataxia (73, 74). Moreover, the manipulation of transcriptional silencing has been used to improve crop plant production and yields (75). Since RNAi-related mechanisms establish sequence-specific heterochromatin in many eukaryotes, we exploited the well-understood process of heterochromatin formation in fission yeast to develop a novel screen for small-molecule modulators of heterochromatin integrity. Collectively, our analyses indicate that HMS-I2 alleviates heterochromatin-mediated gene silencing in both fungal and plant systems but not MEL cells, whereas HMS-I1 abrogates silencing across the fungal, plant, and animal kingdoms. Both HMS-I1 and HMS-I2 were observed to inhibit the in vitro activity of fission yeast class II Clr3 HDAC,
whereas only HMS-I1 inhibited the human subclass IIb enzymes, HDAC6 and HDAC10. Phylogenetic analysis indicates that human HDAC6 and HDAC10 are closely related to Clr3 (76), with a similar domain architecture of the HDAC catalytic domain followed by a conserved C-terminal domain. Although the major substrate of HDAC6 has been reported to be acetylated α-tubulin (77), this enzyme has also been implicated in chromatin regulation and could play a direct role in histone deacetylation (78). HDAC10 possesses HDAC activity and has been implicated in autophagy and cancer (79, 80). Therefore, our cross-species comparisons suggest that type II HDAC enzymes may be conserved targets of HMS-I1 and potentially also HMS-I2.

Inspection of the chemical structure of HMS-I1 and HMS-I2 suggests that their mechanism of action is likely to differ from that of canonical HDAC inhibitors, particularly as neither HMS-I1 or HMS-I2 have obvious zinc-chelating characteristics. HMS-I1 and HMS-I2 may therefore represent a novel class of HDAC inhibitor.

**FIG 8** HMS-I1 reduces the activity of mammalian HDAC6 and HDAC10 in vitro. (A) Fluorescence-based deacetylation assays were used to detect inhibition of recombinant human HDAC6 and HDAC10 activity in vitro at the indicated concentrations of HMS-I1. Error bars indicate the standard deviations from two replicates. (B) Quantification of eGFP transcripts relative to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) transcript levels after siRNA knockdown of HDAC6 and HDAC10 in MEL cells with a β-globin/eGFP reporter inserted with (RL5/pYB-αSat) or without (RL5/pYB) adjacent α-satellite arrays at the RL5 locus. Error bars indicate the standard deviations from three biological replicates. (C) Quantification of HDAC6 and HDAC10 transcripts relative to GAPDH transcript levels after siRNA knockdown of HDAC6 and HDAC10 in RL5/pYB and RL5/pYB-αSat MEL cells. Error bars indicate standard deviations for three biological replicates. *, P < 0.05.
HMS-I1 and HMS-I2 directly target HDAC activity, it remains formally possible that these compounds also affect heterochromatin integrity in vivo by interfering with other activities and/or protein interactions within HDAC complexes. A detailed structure-activity relationship (SAR) analysis will be required to improve potency and further delineate the mechanism of HMS-I1 and HMS-I2 action. Regardless, our discovery of HMS-I1 and HMS-I2 as panspecies inhibitors of heterochromatin-mediated transcriptional gene silencing demonstrates the striking functional conservation of the silencing machinery through eukaryotic evolution. HMS-I1 and HMS-I2 should serve as new chemical probes for dissection of silencing functions in various species and represent possible candidates for early stage drug development in diseases that result from inappropriate gene silencing events.

ACKNOWLEDGMENTS

We thank members of the Allshire lab, Ricardo Almeida, Aileen Greig, Fabio Pucci, and Leemor Joshua-Tor for support and Alison Pidoux for comments on the manuscript. We are grateful to Takeshi Urano and Hiroshi Kimura for the anti-H3K9me2 and anti-H3K9me3 antibodies, respectively, to Hervé Vaucheret for the A. thaliana L5 line, to Vladimir L. Larionov for the MEL RL5 cell lines and input on experiments with MEL cells, and to Shiv Grewal and Janet Partridge for strains and reagents. We also thank Peter Svensson with help in preparing the GEO submission.

E.C. was supported by a scholarship from the Natural Sciences and Engineering Research Council of Canada, and D.J.S-C. was supported by a Canadian Institutes of Health Research postdoctoral fellowship. R.C.A. was supported by the Wellcome Trust (065061 and 095021) and the European Commission Network of Excellence EpiGeneSys (HEALTH-F4-2007-201227).

REFERENCES


A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor.

February 2015 Volume 35 Number 4 mcb.asm.org


protein, Chp1, is required for the establishment of heterochromatin in fission yeast. EMBO J 23:3825–3835. http://dx.doi.org/10.1038/sj.emboj.7600401.


